Imatinib mesylate in thymic epithelial malignancies

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 309-315

  Palmieri, Giovannella ^a   Marino, Mirella ^b   Buonerba, Carlo ^a   Federico, Piera ^a   Conti, Salvatore ^b   Milella, Michele ^b   Petillo, Luigi ^a   Evoli, Amelia ^c   Lalle, Maurizio ^d   Ceribelli, Anna ^b   Merola, Gerardina ^a   Matano, Elide ^a   Sioletic, Stefano ^b   De Placido, Sabino ^a   Di Lorenzo, Giuseppe ^a   Damiano, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

Author keywords

c KIT; Imatinib; Thymic carcinomas; Thymic tumors

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; ASTHENIA; BONE PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EXOPHTHALMOS; FEMALE; HUMAN; HUMAN TISSUE; LEG EDEMA; MALE; MEDIASTINUM TUMOR; MIGRAINE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; THYMIC CARCINOMA; THYMIC EPITHELIAL TUMOR;

ADULT; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 84856708598     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1690-0     Document Type: Review

References (25)

1. WK De Jong JL Blaauwgeers M Schaapveld W Timens TJ Klinkenberg HJ Groen 2008 Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy Eur J Cancer 44 123 130 18068351 10.1016/j.ejca.2007.11.004 (Pubitemid 50009874)
2. Travis WD, Brambilla E, Müller-Hemerlink HK (2004) Tumours of the lung, pleura, thymus and heart. In: Pathology & Genetics series, World Health Organization Classification of Tumours, IARC Press, Lyon
3. A Masaoka Y Monden K Nakahara T Tanioka 1981 Follow-up study of thymomas with special reference to their clinical stages Cancer 48 2485 2492 7296496 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R 1:STN:280:DyaL38%2FkvVektg%3D%3D (Pubitemid 12228012)
4. CB Falkson A Bezjak G Darling, et al. 2009 The management of thymoma: a systematic review and practice guideline J Thorac Oncol 4 911 919 19557895 10.1097/JTO.0b013e3181a4b8e0
5. G Palmieri G Merola P Federico, et al. 2010 Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs) Ann Oncol 21 1168 1172 19880439 10.1093/annonc/mdp483 1:STN:280:DC%2BC3czmtVShsg%3D%3D
6. Blay JY (2010) A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. [Epub ahead of print]
7. JL Hornick CD Fletcher 2007 The role of KIT in the management of patients with gastrointestinal stromal tumors Hum Pathol 38 679 687 17437861 10.1016/j.humpath.2007.03.001 1:CAS:528:DC%2BD2sXkt1ajtLk%3D (Pubitemid 46560810)
8. I Petrini PA Zucali HS Lee 2010 Expression and mutational status of c-kit in thymic epithelial tumors J Thorac Oncol 5 9 1447 1453 20651610 10.1097/JTO.0b013e3181e96e30
9. K Nakagawa Y Matsuno H Kunitoh, et al. 2005 Immunohistochemical KIT (CD117) expression in thymic epithelial tumors Chest 128 140 144 16002927 10.1378/chest.128.1.140 1:CAS:528:DC%2BD2MXnvFyqtrg%3D (Pubitemid 40994465)
10. P Ströbel M Hartmann A Jakob, et al. 2004 Thymic carcinoma with overexpression of mutated KIT and the response to imatinib N Engl J Med 350 25 2625 2626 15201427 10.1056/NEJM200406173502523 (Pubitemid 38758557)
11. MC Heinrich CL Corless GD Demetri, et al. 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 4342 4349 14645423 10.1200/JCO.2003.04.190 1:CAS:528: DC%2BD2cXpsVWqu7Y%3D (Pubitemid 46621810)
12. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
13. J Verweij PG Casali J Zalcberg, et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 1134 15451219 10.1016/S0140-6736(04)17098-0 1:CAS:528: DC%2BD2cXnvVOiu7o%3D (Pubitemid 39296599)
14. H Young R Baum U Cremerius, et al. 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1773 1782 10673991 10.1016/S0959-8049(99)00229-4 1:STN:280:DC%2BD3c7jvV2ntA%3D%3D (Pubitemid 29512308)
15. RP A'Hern 2001 Sample size tables for exact single-stage phase II designs Stat Med 20 6 859 866 11252008 10.1002/sim.721 (Pubitemid 32249085)
16. JD Huizinga L Thuneberg M Klüppel J Malysz HB Mikkelsen A Bernstein 1995 W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity Nature 373 347 349 7530333 10.1038/373347a0 1:CAS:528:DyaK2MXjtlygur0%3D
17. J Paral I Slaninka H Kalabova D Hadzi-Nikolov 2010 Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options Acta Gastroenterol Belg 73 3 349 359 21086937 1:STN:280:DC%2BC3cbnvF2qtg%3D%3D
18. LM Krug JP Crapanzano CG Azzoli, et al. 2005 Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial Cancer 103 10 2128 2131 15812822 10.1002/cncr.21000 1:CAS:528:DC%2BD2MXkslyltbw%3D (Pubitemid 40605121)
19. SJ Hotte EW Winquist E Lamont, et al. 2005 Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study J Clin Oncol 23 3 585 590 15659505 10.1200/JCO.2005.06.125 1:CAS:528:DC%2BD2MXitVartLg%3D (Pubitemid 46224236)
20. WK Huh MW Sill KM Darcy, et al. 2010 Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a gynecologic oncology group phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus Gynecol Oncol 117 2 248 254 20189232 10.1016/j.ygyno.2010.01.002 1:CAS:528:DC%2BC3cXktlCjurk%3D
21. N Girard 2010 Thymic tumors: relevant molecular data in the clinic J Thorac Oncol 10 4 291 295 10.1097/JTO.0b013e3181f209b9
22. G Giaccone A Rajan R Ruijter, et al. 2009 Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas J Thorac Oncol 4 10 1270 1273 20197733 10.1097/JTO.0b013e3181b6be57
23. U Dişel S Oztuzcu AA Beşen, et al. 2011 Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation Lung Cancer 71 109 112 20970876 10.1016/j.lungcan.2010.09.011
24. P Ströbel R Bargou A Wolff, et al. 2010 Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience Br J Cancer 103 196 200 20571495 10.1038/sj.bjc.6605740
25. N Girard R Shen T Guo, et al. 2009 Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas Clin Cancer Res 15 6790 6799 19861435 10.1158/1078-0432.CCR-09-0644 1:CAS:528:DC%2BD1MXhtl2ktL%2FJ